





POSTERIOR CHAMBER PHAKIC IOLS ARE MY LAST CHOICE!

Michael C. Knorz
 Medical Faculty Mannheim, University of Heidelberg
 Mannheim, Germany




Disclosures

- ◉ Alcon C, L
- ◉ Alcon LenSx C, L
- ◉ Optical Express C






Posterior Chamber Phakic IOLs



- ◉ There is no posterior chamber, the iris touches the crystalline lens !
- ◉ Cataract and glaucoma are potential problems

- ◉ Sanders DR, Doney K, Poco M, ICL in treatment of myopia study group
 US FDA clinical trial of the ICL for moderate to high myopia: three-year follow up
Ophthalmology 2004; 111:1683-1692
- ◉ 526 eyes
- ◉ cumulative endothelial cell loss 8.4%-9.7% at three years (3.2% per year)
- ◉ 2.7% anterior subcapsular opacities
- ◉ 0.6% nuclear sclerosis
- ◉ 0.6% cataract extraction and ICL explantation







- ◉ Sanders DR
 Anterior subcapsular opacities and cataracts 5 years after surgery in the Visian Implantable Collamer Lens FDA trial
J Refract Surg 2008; 24:566-570
- ◉ 526 eyes, 311 at 5 years,
- ◉ anterior subcapsular opacities in 6%,
- ◉ 1-2% cataracts, mainly high myopes and older patients


Anterior Chamber Phakic IOLs

- ◉ Anterior chamber provides sufficient space !

Artisan / Verisyse IOL


- Long-term safety established
- FDA approved
 - Difficult to implant
 - Iridectomy required
 - Large incision causes astigmatism
 - Prolonged visual rehabilitation



UMM
UNIVERSITÄT MANNHEIM
Mannheimer Fakultät für Medizin
Abt. Universitätsklinik für Augenheilkunde
Universitätsklinikum Mannheim

AcrySof CACHET Phakic IOL


- not FDA approved, but CE marked
- Single piece, AcrySof® material, angle supported
- Foldable



UMM
UNIVERSITÄT MANNHEIM
Mannheimer Fakultät für Medizin
Abt. Universitätsklinik für Augenheilkunde
Universitätsklinikum Mannheim




1st Implant 6. Dec. 1999, Mannheim



UMM
UNIVERSITÄT MANNHEIM
Mannheimer Fakultät für Medizin
Abt. Universitätsklinik für Augenheilkunde
Universitätsklinikum Mannheim

Cachet IOL Position *in vivo* (no iridectomy/iridotomy required)


Anterior Chamber OCT



UMM
UNIVERSITÄT MANNHEIM
Mannheimer Fakultät für Medizin
Abt. Universitätsklinik für Augenheilkunde
Universitätsklinikum Mannheim

- Knorz MC, Lane SS, Holland S
AcrySof angle-supported phakic IOL for the correction of moderate to high myopia: Three-year interim results of an international multicenter study (*JCRS 2011; 37: 469-480*)
- 360 eyes
Surgical ECC loss: (pre-op to 6 months) 3.31% centrally and 2.98% peripherally
Chronic ECC loss: (annualized from 6 months to 3 years) 0.4% centrally and 1.1% peripherally

UMM
UNIVERSITÄT MANNHEIM
Mannheimer Fakultät für Medizin
Abt. Universitätsklinik für Augenheilkunde
Universitätsklinikum Mannheim



- ### Conclusion – AC Phakic IOL ideal !
- ◉ AC is ideal place to implant phakic IOLs !
 - ◉ Which AC Phakic IOLs are safe ?
 - Verisyse IOL: large incision, difficult, iridectomy
 - Acrysof Cachet: small incision, easy, no iridectomy
 - Both of the above: Long-term safety established (no chronic EC loss)
- UMM
UNIVERSITÄT MANNHEIM
Fakultät für Medizin
Klinische Ophthalmologie
Mannheim

THANK YOU !

UMM
UNIVERSITÄT MANNHEIM
Fakultät für Medizin
Klinische Ophthalmologie
Mannheim